Infliximab biosimilar GP1111: a review of 5 years’ post-approval experience

References

• Remicade summary of product characteristics [Internet]. European Medicines Agency. 2022 [updated 2022 Sep 26; cited 2022 Nov 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf
   Google Scholar
• REMICADE highlights of prescribing information [Internet]. US Food and Drug Administration. 2020 [cited 2023 Nov 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103772s5401lbl.pdf
   Google Scholar
• McClellan JE, Conlon HD, Bolt MW, et al. The ‘totality-of-the-evidence’ approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product. Therap Adv Gastroenterol. 2019;12:1756284819852535. doi: 10.1177/1756284819852535
   Web of Science ®Google Scholar
• Kornbluth A. Infliximab approved for use in crohnʼs disease: a report on the FDA GI advisory committee conference. Inflamm Bowel Dis. 1998;4:328–329. doi: 10.1097/00054725-199811000-00014
   PubMedGoogle Scholar
• Smolen JS, Emery P. Infliximab: 12 years of experience. Arthritis Res Ther. 2011;13:S2. doi: 10.1186/1478-6354-13-S1-S2
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn’s disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24:490–501. doi: 10.1093/ibd/izx072
   PubMedGoogle Scholar
• Wilhelm SM, McKenney KA, Rivait KN, et al. A review of infliximab use in ulcerative colitis. Clin Ther. 2008;30:223–230. doi: 10.1016/j.clinthera.2008.02.014
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–699. doi: 10.1136/annrheumdis-2019-216655
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924–939. doi: 10.1002/acr.24596
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis. 2020;14:4–22. doi: 10.1093/ecco-jcc/jjz180
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517. doi: 10.1038/ajg.2018.27
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160:2496–2508. doi: 10.1053/j.gastro.2021.04.022
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–1207. doi: 10.1016/j.crohns.2014.04.005
   PubMed Web of Science ®Google Scholar
• de Zoeten EF, Pasternak BA, Mattei P, et al. Diagnosis and treatment of perianal Crohn disease: NASPGHAN clinical report and consensus statement. J Pediatr Gastroenterol Nutr. 2013;57:401–412. doi: 10.1097/MPG.0b013e3182a025ee
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2021;16:2–17. doi: 10.1093/ecco-jcc/jjab178
   Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450–1461. doi: 10.1053/j.gastro.2020.01.006
   PubMed Web of Science ®Google Scholar
• Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn’s and Colitis Organization and the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67:292–310. doi: 10.1097/mpg.0000000000002036
   PubMed Web of Science ®Google Scholar
• Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol. 2011;106:574–588. doi: 10.1038/ajg.2010.481
   PubMed Web of Science ®Google Scholar
• Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82:19–34. doi: 10.1136/ard-2022-223296
   PubMed Web of Science ®Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken). 2019;71:1285–1299. doi: 10.1002/acr.24025
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700–712. doi: 10.1136/annrheumdis-2020-217159
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5–32. doi: 10.1002/art.40726
   PubMed Web of Science ®Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris – part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34:2461–2498. doi: 10.1111/jdv.16915
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–1072. doi: 10.1016/j.jaad.2018.11.057
   PubMed Web of Science ®Google Scholar
• Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80:99–113. doi: 10.1007/s40265-020-01256-5
   PubMed Web of Science ®Google Scholar
• Car E, Vulto AG, Houdenhoven MV, et al. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023;14:1151764. doi: 10.3389/fphar.2023.1151764
   PubMed Web of Science ®Google Scholar
• Zessly summary of product characteristics [Internet]. European Medicines Agency. 2023 [Updated 2023 July 14; cited 2023 Nov 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/zessly-epar-product-information_en.pdf
   Google Scholar
• IXIFI highlights of prescribing information [Internet]. US Food and Drug Administration. 2020 [updated 2020 Jan; cited 2020 Nov 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761072s006lbl.pdf
   Google Scholar
• Zessly (infliximab) summary of opinion (initial authorisation) [Internet]. European Medicines Agency. 2018 [updated 2018 Mar 22; cited 2023 Mar 22]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-zessly_en.pdf
   Google Scholar
• Daller J. Biosimilars: a consideration of the regulations in the United States and European Union. Regul Toxicol Pharmacol. 2016;76:199–208. doi: 10.1016/j.yrtph.2015.12.013
   PubMed Web of Science ®Google Scholar
• Derzi M, Johnson TR, Shoieb AM, et al. Nonclinical evaluation of PF-06438179: a potential biosimilar to Remicade® (infliximab). Adv Ther. 2016;33:1964–1982. doi: 10.1007/s12325-016-0403-9
   PubMed Web of Science ®Google Scholar
• Lerch TF, Sharpe P, Mayclin SJ, et al. Crystal structures of PF-06438179/GP1111, an infliximab biosimilar. BioDrugs. 2020;34:77–87. doi: 10.1007/s40259-019-00390-1
   PubMed Web of Science ®Google Scholar
• CHMP assessment report: Zessly (international non-proprietary name: infliximab). European Medicines Agency; 2018 [Updated 2018 Mar 22; cited 2023 Nov 16]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/zessly-epar-public-assessment-report_en.pdf
   Google Scholar
• Palaparthy R, Rehman MI, von Richter O, et al. Population pharmacokinetics of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderately to severely active rheumatoid arthritis. Expert Opin Biol Ther. 2019;19:1065–1074. doi: 10.1080/14712598.2019.1635583
   PubMed Web of Science ®Google Scholar
• Palaparthy R, Udata C, Hua SY, et al. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01). Expert Rev Clin Immunol. 2018;14:329–336. doi: 10.1080/1744666X.2018.1446829
   PubMed Web of Science ®Google Scholar
• Al-Salama ZT. PF-06438179/GP1111: an infliximab biosimilar. BioDrugs. 2018;32:639–642. doi: 10.1007/s40259-018-0310-5
   PubMed Web of Science ®Google Scholar
• Cohen SB, Alten R, Kameda H, et al. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy. Arthritis Res Ther. 2018;20:155. doi: 10.1186/s13075-018-1646-4
   PubMed Web of Science ®Google Scholar
• Kameda H, Uechi E, Atsumi T, et al. A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: a subgroup analysis. Int J Rheum Dis. 2020;23:876–881. doi: 10.1111/1756-185X.13846
   PubMed Web of Science ®Google Scholar
• Alten R, Batko B, Hala T, et al. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. RMD Open. 2019;5:e000876. doi: 10.1136/rmdopen-2018-000876
   PubMed Web of Science ®Google Scholar
• Cohen SB, Radominski SC, Kameda H, et al. Long-term efficacy, safety, and immunogenicity of the infliximab (IFX) biosimilar, PF-06438179/GP1111, in patients with rheumatoid arthritis after switching from reference IFX or continuing biosimilar therapy: week 54-78 data from a randomized, double-blind, phase III trial. BioDrugs. 2020;34:197–207. doi: 10.1007/s40259-019-00403-z
   PubMed Web of Science ®Google Scholar
• Lee YH, Song GG. Comparative efficacy and safety of infliximab and its biosimilars in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis. Z Rheumatol. 2023;82:114–122. doi: 10.1007/s00393-021-01040-0
   PubMed Web of Science ®Google Scholar
• Nabi H, Hendricks O, Jensen DV, et al. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry. RMD Open. 2022;8:e002560. doi: 10.1136/rmdopen-2022-002560
   PubMed Web of Science ®Google Scholar
• RADS recommendation regarding the use of biosimilar infliximab and etanercept. 2016. [updated 2016 Jun 12; cited 2024 Jun 12]. Available from: https://www.regioner.dk/media/3488/rads-notat-om-anvendelsen-af-biosimilaere-juni-2016.pdf
   Google Scholar
• Dipasquale V, Pellegrino S, Ventimiglia M, et al. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease. Eur J Gastroenterol Hepatol. 2022;34:1007–1014. doi: 10.1097/meg.0000000000002408
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Casà A, Renna S, et al. Switching from SB2 to PF-06438179/GP1111 and back in inflammatory bowel disease: “the superswitchers”. Dig Liver Dis. 2023;55:424–425. doi: 10.1016/j.dld.2022.12.008
   PubMedGoogle Scholar
• Vimpolsek M, Gottar-Guillier M, Rossy E. Assessing the extended in-use stability of the infliximab biosimilar PF-06438179/GP1111 following preparation for intravenous infusion. Drugs R D. 2019;19:127–140. doi: 10.1007/s40268-019-0264-1
   PubMed Web of Science ®Google Scholar
• Osiri M, Dilokthornsakul P, Chokboonpium S, et al. Budget impact of sequential treatment with biologics, biosimilars, and targeted synthetic disease-modifying antirheumatic drugs in Thai patients with rheumatoid arthritis. Adv Ther. 2021;38:4885–4899. doi: 10.1007/s12325-021-01867-8
   PubMed Web of Science ®Google Scholar
• Dipasquale V, Martinelli M, Aloi M, et al. Real-life use of biosimilars in pediatric inflammatory bowel disease: a nation-wide web survey on behalf of the SIGENP IBD working group. Paediatr Drugs. 2022;24:57–62. doi: 10.1007/s40272-021-00486-8
   PubMed Web of Science ®Google Scholar
• Taylor PC, Woods M, Rycroft C, et al. Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. Rheumatology (Oxford). 2021;60:4972–4981. doi: 10.1093/rheumatology/keab464
   PubMedGoogle Scholar
• Danese S, Allez M, van Bodegraven AA, et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig Dis. 2019;37:266–283. doi: 10.1159/000496739
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease–an update. J Crohns Colitis. 2017;11:26–34. doi: 10.1093/ecco-jcc/jjw198
   PubMed Web of Science ®Google Scholar
• Park SH, Park JC, Lukas M, et al. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. Intest Res. 2020;18:34–44. doi: 10.5217/ir.2019.09147
   PubMed Web of Science ®Google Scholar
• Goll GL, Kvien TK. Improving patient access to biosimilar tumor necrosis factor inhibitors in immune-mediated inflammatory disease: lessons learned from Norway. Expert Opin Biol Ther. 2023;23:1203–1209. doi: 10.1080/14712598.2023.2273938
   PubMed Web of Science ®Google Scholar
• Alanaeme CJ, Sarvesh S, Li CY, et al. Adherence patterns in naïve and prevalent use of infliximab and its biosimilar. BMC Rheumatol. 2022;6:65. doi: 10.1186/s41927-022-00295-7
   PubMedGoogle Scholar
• Khoo T, Sidhu N, Marine F, et al. Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions. BMC Rheumatol. 2022;6:79. doi: 10.1186/s41927-022-00309-4
   PubMedGoogle Scholar